The PD-1/PD-L1 Inhibitor Screening Cell-Based Assay is a bioluminescent cell-based assay that can be used to screen and profile inhibitors of PD-1:PD-L1 or PD-1:PD-L2 interaction. The assay consists of two main components: • PD-1 Effector cells (PD-1/NFAT reporter-Jurkat cells): Reporter Jurkat T cells expressing firefly luciferase gene under the control of NFAT response elements and also constitutively expressing human PD-1. These cryopreserved cells are provided in a thaw-and-use format that does not require cell propagation. •Expression vectors for TCR activator, human PD-L1, and human PD-L2: Transfection-ready vectors are used to transfect cells to create the target cells that overexpress PD-L1 or PD-L2 and an engineered cell surface T cell receptor (TCR) activator.

Programmed cell death 1, PDCD1, PD-1, PD1, SLEB2, CD279, HPD-L, Programmed Cell Death 1 Ligand 1, PDL1, PD-L1, B7 homolog 1, B7H1, B7-H1, CD274, PDCD1L1, Programmed Cell Death 2 Ligand 2, PDL2, PD-L2, CD273, PDCDL1G2, B7-DC, activity assay kit

COMPONENTS:

Store cell line in liquid nitrogen immediately upon receipt. Store other components as described below. Stable for at least 6 months from date of receipt when stored as directed.

• Screen for inhibitors of PD-1 signaling in a cellular context

• Characterize the biological activity of PD-1 and its interactions with ligands

Immunotherapy

Assay Kit